Figure Legends for Supplemental Figures:

Supplemental Figure 1: Flow-cytometry analysis of LTLT-Ca cells treated with entinostat in presence of MG-132, NH₄Cl or the combination of MG-132 and NH₄Cl: LTLT-Ca cells were treated with ENT (1μM) alone or in presence of MG-132 (5μM) or NH₄Cl (100μM) or both. Protein expression in the cells was examined by flow-cytometry for expression of Her-2 protein.

Supplemental Figure 2: Western blotting analysis of LTLT-Ca cells treated with entinostat in presence of MG-132: LTLT-Ca cells were treated with letrozole + MG-132 (5μM) in presence or absence of ENT (1μM). Her-2 protein in the cell lysates was immunoprecipitated and then the blot was probed for poly-ubiquitination. Increased poly-ubiquitination is seen in LTLT-Ca cells treated with ENT.

Supplemental Figure 3: RT-PCR analysis of Her-2 mRNA levels in MCF-7Ca and LTLT-Ca cells: Relative level of Her-2 mRNA in MCF-7Ca and LTLT-Ca cells was analyzed by real-time RT-qPCR. Cells were treated with ENT (1μM) alone or in presence of actinomycin D (5μM) and cells were collected at indicated time points. RNA was isolated, quantified and diluted to 0.08μg/μl. Total 0.64μg of RNA was reverse transcribed and Her-2 was amplified using real-time qPCR as described in Materials and Methods. Graph represents relative levels (±SEM) of Her-2 mRNA compared to 0 hour control (set at 1).